Anti–Muc1 Nanobody Can Synergize the Tamoxifen and Herceptin Effects on Breast Cancer Cells by Inducing Er, Pr and Her2 Overexpression

Anti–Muc1 Nanobody Can Synergize the Tamoxifen and Herceptin Effects on Breast Cancer Cells by Inducing Er, Pr and Her2 Overexpression Publisher Pubmed

Shokrollahi Barough M^{1, 2, 3} ; Jalili N² ; Shafiee S² ; Salehi M² ; Naseri N² ; Javidi MA⁴ ; Hosseinzadeh A² ; Farahmand L²

Show Affiliations

1. ATMP Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, 1517964311, Iran
2. Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
3. Department of Immunology, Iran University of Medical Sciences, Tehran, 1449614535, Iran
4. Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran

Source: International Immunopharmacology Published:2023

Abstract

Introduction: One of the most pressing concerns associated with breast cancer-targeted therapies is resistance to Tamoxifen and Herceptin. Such drug resistance is usually characterized by reduced expression of certain cell surface receptors. Some biological regimens can induce perceptible overexpression of these receptors in favor of drug responsiveness. Material and Methods: In this research, drug-responsive MCF-7 and SKBR-3, along with drug-resistant MCF-7R (Tamoxifen resistant) and JIMT-1 (Herceptin resistant) breast cancer cell lines in 2D and 3D cultures were exposed to anti-MUC1 nanobody and then assessed for their ER, PR, and HER2 gene and protein expression using qRT-PCR and immunofluorescent staining analyses. Cell viability and the synergistic relationships of combination treatments were determined with MTT assay followed by CompuSyn software. Apoptotic cells were evaluated with Annexin V/propidium Iodide (PI) and acridine orange/ethidium bromide (AO/EB) staining. Results: Anti-MUC1 exposure elevated the expression levels of ER (42 folds), PR (18.5 folds), and HER2 (4.7 folds). As a result of co-treatment, the IC50 levels for Tamoxifen and Herceptin were reduced by up to 10 and 3 folds, respectively. MCF-7R cells responded positively to Tamoxifen, as evidenced by a 5-fold reduction in the IC50 and enhanced apoptosis. Conclusion: The ER, PR, and HER2 overexpression after MUC1 blocking could signal drug hypersensitization and facilitate drug resistance management. © 2023 Elsevier B.V.

Related Docs

View other Related Docs

1. Clinical Evidence on the Magnitude of Change in Growth Pathway Activity in Relation to Tamoxifen Resistance Is Required, Current Cancer Drug Targets (2018)

2. Muc1 Induces Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer, Expert Review of Anticancer Therapy (2017)

3. Evaluating Human Epidermal Growth Factor Receptor 2 Roles in the Efficacy of Tamoxifen Treatment in Breast Cancer, a Systematic Review, Pharmacological Reports (2021)

4. Crosstalk Between Muc1 and Vegf in Angiogenesis and Metastasis: A Review Highlighting Roles of the Muc1 With an Emphasis on Metastatic and Angiogenic Signaling, Cancer Cell International (2021)

5. Recombinant Nanobody Against Muc1 Tandem Repeats Inhibits Growth, Invasion, Metastasis, and Vascularization of Spontaneous Mouse Mammary Tumors, Molecular Oncology (2022)

6. Muc1 Is a Potential Target to Overcome Trastuzumab Resistance in Breast Cancer Therapy, Cancer Cell International (2022)

7. Significant Role of Muc1 in Development of Resistance to Currently Existing Anti-Cancer Therapeutic Agents, Current Cancer Drug Targets (2018)

8. Challenges of Endocrine Therapy in Breast Cancer, Cancer Genetics and Psychotherapy (2017)

Experts (# of related papers)

Nima Rezaei (1)

Style	Citing Format
MLA	Shokrollahi Barough M, et al.. "Anti–Muc1 Nanobody Can Synergize the Tamoxifen and Herceptin Effects on Breast Cancer Cells by Inducing Er, Pr and Her2 Overexpression." International Immunopharmacology, vol. 124, no. , 2023, pp. -.
APA	Shokrollahi Barough M, Jalili N, Shafiee S, Salehi M, Naseri N, Javidi MA, Hosseinzadeh A, Farahmand L (2023). Anti–Muc1 Nanobody Can Synergize the Tamoxifen and Herceptin Effects on Breast Cancer Cells by Inducing Er, Pr and Her2 Overexpression. International Immunopharmacology, 124(), -.
Chicago	Shokrollahi Barough M, Jalili N, Shafiee S, Salehi M, Naseri N, Javidi MA, Hosseinzadeh A, Farahmand L. "Anti–Muc1 Nanobody Can Synergize the Tamoxifen and Herceptin Effects on Breast Cancer Cells by Inducing Er, Pr and Her2 Overexpression." International Immunopharmacology 124, no. (2023): -.
Harvard	Shokrollahi Barough M et al. (2023) 'Anti–Muc1 Nanobody Can Synergize the Tamoxifen and Herceptin Effects on Breast Cancer Cells by Inducing Er, Pr and Her2 Overexpression', International Immunopharmacology, 124(), pp. -.
Vancouver	Shokrollahi Barough M, Jalili N, Shafiee S, Salehi M, Naseri N, Javidi MA, et al.. Anti–Muc1 Nanobody Can Synergize the Tamoxifen and Herceptin Effects on Breast Cancer Cells by Inducing Er, Pr and Her2 Overexpression. International Immunopharmacology. 2023;124():-.
BibTex	@article{ author = {Shokrollahi Barough M and Jalili N and Shafiee S and Salehi M and Naseri N and Javidi MA and Hosseinzadeh A and Farahmand L}, title = {Anti–Muc1 Nanobody Can Synergize the Tamoxifen and Herceptin Effects on Breast Cancer Cells by Inducing Er, Pr and Her2 Overexpression}, journal = {International Immunopharmacology}, volume = {124}, number = {}, pages = {-}, year = {2023} }
RIS	TY - JOUR AU - Shokrollahi Barough M AU - Jalili N AU - Shafiee S AU - Salehi M AU - Naseri N AU - Javidi MA AU - Hosseinzadeh A AU - Farahmand L TI - Anti–Muc1 Nanobody Can Synergize the Tamoxifen and Herceptin Effects on Breast Cancer Cells by Inducing Er, Pr and Her2 Overexpression JO - International Immunopharmacology VL - 124 IS - SP - EP - PY - 2023 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract